Evaluate Pharma Alternative: Daily Trial Monitoring Without Enterprise Pricing

Evaluate Pharma (now part of Norstella) is built for enterprise pharma intelligence — consensus forecasts, deal analytics, portfolio strategy. DataLookout is built for one thing: knowing when trials change.

Feature Evaluate Pharma DataLookout
Pricing$15,000-50,000+/year$0-99/month
ContractAnnual enterpriseMonthly, cancel anytime
Trial change detectionNot a core featureCore feature — daily, severity-classified
Consensus revenue forecastsYes — primary differentiatorNo
Deal and M&A analyticsYesNo
Status change alertsNo automated field-level alertsAutomatic with severity classification
Endpoint trackingShown in profiles, not diffedAutomatic before/after detection
Enrollment monitoringStatic count displayDelta detection (+200, +40%)
Data sourceProprietary + public sourcesClinicalTrials.gov (45,000+ trials)
Setup timeWeeks (enterprise procurement)2 minutes
Free tierNoYes — free forever

What Evaluate Pharma does well

Evaluate Pharma is a financial intelligence platform for the pharma industry. Its core strength is consensus revenue forecasts — what analysts expect a drug to earn. It also covers deal flow, portfolio valuation, and strategic benchmarking.

Where DataLookout fits

Evaluate Pharma answers the question: what will this drug be worth? DataLookout answers: what changed in this trial today?

These are different tools for different jobs. If you need revenue forecasts and NPV models, Evaluate is the right choice. If you need to know that a competitor expanded from 44 to 61 trial sites yesterday, or that their primary endpoint was rewritten, DataLookout catches that automatically.

At $0-99/month, many teams use DataLookout as a daily monitoring layer alongside (or instead of) enterprise tools.

Try DataLookout free

1 sponsor + 1 disease watchlist with daily change detection. Free forever, no credit card.

Get Started Free